Global reach and expertise in Rare Disease
MA = Marketing Authorisation
30
Available in 30+ countries
100
Number of employees
20
Established dedicated team in 20+ countries including the US and Europe
OUR MISSION
Transforming Rare Disease Treatment
We believe patients with a rare disease should have access to innovative treatment that improves their care and positively impacts their lives and those of their loved ones.
At Orphalan we strive to develop rare disease treatments to improve patients’ lives.
At Orphalan we identify, develop, and provide access to innovative treatments for patients with rare diseases to make a positive and meaningful difference. We work together by listening to patients and putting them first, which enables us to provide treatments and services that work for them.
Learn More
Read the latest news
All the latest company news, events and updates.
Orphalan becomes the first European company to enter in China’s Wilson Disease market
Orphalan becomes the first European company to enter in China’s Wilson Disease market
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
Tackling rare diseases: Wilson disease patient and millions more like her need help
Tackling rare diseases: Wilson disease patient and millions more like her need help
Why We Should Care About Rare Disease Research – Life Science Leader
Why We Should Care About Rare Disease Research – Life Science Leader
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today
